Artikel
Intravitreal triamcinolone in the treatment of diabetic hard exudates
Suche in Medline nach
Autoren
Veröffentlicht: | 18. September 2006 |
---|
Gliederung
Text
Objective
To report short-term efficacy of intravitreal triamcinolone acetonide in patients with massive hard exudates.
Methods
We enrolled 16 patients (19 eyes) with massive hard exudates involving the fovea in a prospective noncomparative interventional study. All patients received a single intravitreal injection of 4 mg of triamcinolone. We evaluated visual acuity, resolution of hard exudates and postoperative complications after the injection.
Results
After a mean follow-up time of 6.4 months average visual acuity improved from 0,05 to 0,1. Thirteen eyes had an initial visual acuity ranging from 0,0125 to 0,025. None of these eyes achieved visual acuity better than 0,075. Resolution of hard exudates was noted in all eyes, with complete resolution being noticed in 5 eyes and partial resolution in 14 eyes. Intraocular pressure elevation, requiring topical medication was noted in 4 eyes. We had no serious complications, such as endophthalmitis.
Conclusions
Triamcinolone acetonide seems to be beneficial in reducing hard exudates and improving visual acuity in diabetic patients. Further evaluation of long-term safety and efficacy of triamcinolone is warranted.